Highlights FUSN PHAR

Equities

FUSN

CA36118A1003

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
21.48 ^USD	+0.47%		+0.14%	+123.52%

05-09	Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	CI
05-07	Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	05-09	CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	04-09	CI
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca	03-20	MT
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20	CI
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16	03-20	MT
Sector Update: Health Care Stocks Rise Late Afternoon	03-19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	03-19	MT
Sector Update: Health Care	03-19	MT
Top Midday Gainers	03-19	MT
Top Stories at Midday: February US Housing Starts Rise; AstraZeneca to Acquire Fusion Pharmaceuticals; IFF to Sell Pharma Solutions Unit; Unilever to Spin Off Ice Cream Unit; MicroStrategy Completes Notes Offering; Super Micro Computer Files Shelf; Nvidia Unveils Latest GPU	03-19	MT
Fed Policy Meeting in Focus as Exchange-Traded Funds, Equity Futures Fall Pre-Bell Tuesday	03-19	MT
AstraZeneca Strikes $2.4 Billion Deal to Buy Fusion Pharmaceuticals	03-19	MT
AstraZeneca to Acquire Fusion Pharmaceuticals for $2.4 Billion; Fusion Shares Rise Pre-Bell	03-19	MT
Fusion Pharmaceuticals Inc. agreed to acquire Exclusive Worldwide License for Actinium-Based PSMA Targeted Radiotherapy from Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.	02-15	CI
Fusion Pharmaceuticals Outlines Fund Guidance, Operational Updates; Shares Surge Premarket	01-05	MT
Fusion Pharmaceuticals Outlines Fund Guidance, Operational Updates; Shares Rise After Hours	01-04	MT
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says	12-27	MT
Fusion Pharmaceuticals 'Last Available Target' With Solid Supply Chain After Point Biopharma, RayzeBio Takeovers, Oppenheimer Says	12-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights FUSN PHAR

Equities

FUSN

CA36118A1003

Highlights

Filters